FAERSデータベースに基づいて,子供と成人の間でドピルマブに関連した有害事象の信号の差異の分析
Jing Zhou1, Yuanyuan Xie1, Pengcheng Du1
1Department of Clinical Pharmacy, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, China.
European journal of pharmacology
|August 30, 2025
まとめ
ドピルマブに対する有害事象 (ADEs) は,子供と成人の間で有意に異なります. これらの年齢特有の安全性プロフィールを理解することは,ドゥピルマブモニタリングを最適化し,患者の安全性を確保するために不可欠です.
科学分野:
- 薬用警戒について
- 臨床薬理学
- 小児医学
背景:
- デュピルマブは様々な炎症性疾患に使用される生物学的治療法です.
- 承認後の安全性データは,実際の薬物の有害事象 (ADEs) を理解するために不可欠です.
- 小児と成人のADEプロフィールの違いについては,具体的な分析が必要である.
研究 の 目的:
- ドピルマブの承認後の有害事象 (ADEs) を小児と成人の集団で比較する.
- この分析のために,FDAの有害事象報告システム (FAERS) のデータを活用する.
- デピルマブの安全な臨床使用について,年齢特有のリスクを特定する.
主な方法:
- FAERSデータベース (2017年第2四半期〜2024年第4四半期) からドピルマブに関連したADEデータを抽出した.
- 小児 (18歳未満) と成人 (18歳以上) に分類されたデータ
- 分析されたシステム・オルガン・クラス (SOC) と,有意なADE信号の好ましい用語 (PT)
主要な成果:
- 分析されたADE報告210300件:子供2065件,成人112508件.
- 各グループで126件の一般的な有害事象 (例えば,リバウンドエクゼマ) とユニークな有害事象 (24件は子供で,156件は成人) が確認された.
- ADEの発症までの平均時間は,子供では0日,成人では14日でした.
結論:
- 小児患者と成人患者のADEプロフィールには大きな違いがあります.
- 安全にドピルマブを使用するためには,年齢特有のモニタリング戦略が必要である.
- 臨床医は,用紙に記載されていない潜在的な高リスクシグナルに注意する必要があります.
関連する概念動画
Pharmacovigilance
983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Drug Regulation
1.8K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.8K
Allergic Drug Reactions
972
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
972
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
293
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
293
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K


